Astonishing response to Cetuximab in metastatic nasopharyngeal carcinoma: a case report.
V. 172 N. 4 (2021), Case report
V. 172 N. 4 (2021)

Astonishing response to Cetuximab in metastatic nasopharyngeal carcinoma: a case report.: doi: 10.7417/CT.2021.2327

Case report
Pubblicato 2021-07-11
L. Raimondi
Oncology - ASL Latina, District 1, University of Rome “Sapienza,” Aprilia (LT)
L. Rossi
Oncology - ASL Latina, District 1, University of Rome “Sapienza,” Aprilia (LT)
G. Cimino
Department of Medical Oncology, Sapienza University of Rome, Medical and Surgical Sciences and Biotechnology, Rome, Italy
E. Gozzi
Oncology - ASL Latina, District 1, University of Rome “Sapienza,” Aprilia (LT)
PDF

Parole chiave

metastatic nasopharyngeal carcinoma
Cetuximab
disease control

Abstract

Nasopharyngeal carcinoma, one of the most common head and neck cancers in Southeast Asia, is uncommon in Western countries and it is frequently diagnosed in advanced stage. Chemotherapy given with radiation therapy, followed by more chemotherapy, is the standard of care of stage IV nasopharyngeal carcinoma but Cetuximab, an epidermal growth factor (EGFR) inhibitor, is now making its way in the treatment of locoregionally advanced nasopharyngeal carcinoma.
We report a case of 58 years old patient with metastatic nasopharyngeal carcinoma with an astonishing response to Cetuximab. At the time of writing, the patient is still in treatment with Cetuximab with excellent disease control.

PDF